Johnathan K. Joffe

Leeds, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 17, 2022

Reply to Torgrim Tandstad. The New Standard Adjuvant Treatment for High-risk Stage 1 Nonseminoma: Reducing the Treatment Burden and Maximizing Long-term Survival. Eur Urol 2020;77:352-3.

Reply to Torgrim Tandstad. The New Standard Adjuvant Treatment for High-risk Stage 1 Nonseminoma: Reducing the Treatment Burden and Maximizing Long-term Survival. Eur Urol 2020;77:352-3.

Journal: European urology

Published: May 05, 2020

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.

Journal: The Lancet. Oncology

Published: October 16, 2019

The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis.

The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis.

Journal: European urology

Published: May 22, 2019

Evaluation of the "Shared Community Follow-up" after a germ cell tumour-A novel initiative for remote cancer follow-up enhanced by online patient-reported outcome measures.

Evaluation of the "Shared Community Follow-up" after a germ cell tumour-A novel initiative for remote cancer follow-up enhanced by online patient-reported outcome measures.

Journal: European journal of cancer care

Published: May 22, 2019

Medical Oncology Workload in Europe: One Continent, Several Worlds.

Medical Oncology Workload in Europe: One Continent, Several Worlds.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Published: January 22, 2019

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).

Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).

Journal: Journal of bone oncology

Published: September 03, 2018

Early warnings and repayment plans: novel trial management methods for monitoring and managing data return rates in a multi-centre phase III randomised controlled trial with paper Case Report Forms.

Early warnings and repayment plans: novel trial management methods for monitoring and managing data return rates in a multi-centre phase III randomised controlled trial with paper Case Report Forms.

Journal: Trials

Published: August 28, 2018

Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK.

Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK.

Journal: British journal of cancer

Published: March 14, 2018

Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone.

Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone.

Journal: The Journal of clinical endocrinology and metabolism

Published: September 12, 2017

COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.

COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 22, 2017

A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3).

A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 23, 2017

Showing 1-12 of 19

Last Updated: 09/26/2026